Cue Biopharma, INC. (CUE) — 8-K Filings

8-K Filings (19)

• Cue Biopharma Files 8-K on Bylaw Amendments — Apr 22, 2026 Risk: medium
  On April 22, 2026, Cue Biopharma, Inc. filed an 8-K report detailing amendments to its Articles of Incorporation or Bylaws. This filing indicates potential chan
• Cue Biopharma Files 8-K: Other Events — Apr 7, 2026 Risk: low
  On April 1, 2026, Cue Biopharma, Inc. filed an 8-K report detailing other events. The filing does not contain specific financial figures or significant business
• Cue Biopharma Files 8-K: Material Agreement, Other Events — Dec 19, 2025 Risk: medium
  On December 19, 2025, Cue Biopharma, Inc. filed an 8-K report. The filing indicates a material definitive agreement was entered into, and also reports other eve
• 8-K Filing — Nov 24, 2025
• Cue Biopharma Announces Board Changes and Officer Compensation Updates — Nov 20, 2025 Risk: medium
  On November 17, 2025, Cue Biopharma, Inc. reported a change in its board of directors, with the election of new directors and the departure of existing ones. Th
• Cue Biopharma Files 8-K: Material Agreement, Financials — Nov 6, 2025 Risk: medium
  On November 6, 2025, Cue Biopharma, Inc. filed an 8-K report. The filing indicates a material definitive agreement was entered into, and also includes Regulatio
• Cue Biopharma Announces Board and Officer Changes — Sep 29, 2025 Risk: medium
  Cue Biopharma, Inc. announced on September 26, 2025, changes in its board and officer composition. The company filed an 8-K report detailing the departure of di
• Cue Biopharma Enters Material Definitive Agreement — Jul 1, 2025 Risk: medium
  On June 30, 2025, Cue Biopharma, Inc. entered into a material definitive agreement. The company, formerly known as Imagen Biopharma, Inc., is incorporated in De
• Cue Biopharma Reports Director/Officer Changes & Corporate Updates — Jun 10, 2025 Risk: medium
  Cue Biopharma, Inc. filed an 8-K on June 10, 2025, reporting several key events as of June 4, 2025. These include the departure of directors or certain officers
• Cue Biopharma Files 8-K on Material Agreement — Apr 15, 2025 Risk: medium
  On April 14, 2025, Cue Biopharma, Inc. filed an 8-K report detailing a material definitive agreement. The filing also covers results of operations and financial
• Cue Biopharma Enters Material Definitive Agreement — Apr 14, 2025 Risk: medium
  On April 10, 2025, Cue Biopharma, Inc. entered into a material definitive agreement. The filing does not provide specific details about the agreement, its count
• Cue Biopharma Announces Board and Executive Changes — Mar 12, 2025 Risk: medium
  Cue Biopharma, Inc. announced on March 10, 2025, changes in its board of directors and executive compensation arrangements. The filing details the departure of
• Cue Biopharma Files 8-K on Shareholder Votes and Financials — Oct 8, 2024 Risk: low
  On October 8, 2024, Cue Biopharma, Inc. filed an 8-K report. The filing indicates that the company is submitting matters to a vote of its security holders and a
• Cue Biopharma Enters Material Definitive Agreement — Oct 4, 2024 Risk: medium
  On October 2, 2024, Cue Biopharma, Inc. entered into a material definitive agreement. The company, formerly known as Imagen Biopharma, Inc., is incorporated in
• Cue Biopharma Enters Material Definitive Agreement — Sep 27, 2024 Risk: medium
  On September 26, 2024, Cue Biopharma, Inc. entered into a material definitive agreement. The filing also notes other events and includes financial statements an
• Cue Biopharma Files 8-K on Executive and Director Changes — Sep 3, 2024 Risk: medium
  On August 28, 2024, Cue Biopharma, Inc. filed an 8-K report detailing changes in its executive and director positions. The filing includes information on the el
• Cue Biopharma Faces Nasdaq Delisting — Aug 16, 2024 Risk: high
  Cue Biopharma, Inc. filed an 8-K on August 15, 2024, to report its failure to meet the minimum bid price requirement for continued listing on the Nasdaq Capital
• Cue Biopharma Appoints New CMO, Adds Director — Jul 25, 2024 Risk: medium
  On July 24, 2024, Cue Biopharma, Inc. announced the appointment of Dr. Anjana Shah as Chief Medical Officer and the election of Ms. Jennifer L. Morgan to its Bo
• Cue Biopharma Files 8-K on Director/Officer Changes — Jun 7, 2024 Risk: medium
  On June 5, 2024, Cue Biopharma, Inc. filed an 8-K report detailing changes in its board of directors and executive officers. The filing includes information on

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX